Boston Scientific has announced that the National Institute for Health and Care Excellence (NICE), has issued guidance recommending the use of the HeartLogic heart failure diagnostic as an option for managing heart failure in patients with cardiac implantable electronic devices.
“Early prediction of heart failure events enables physicians to intervene sooner—leading to better patient outcomes and reduced burden on the healthcare system—and we believe this decision will broaden the use of the HeartLogic heart failure diagnostic among physicians,” said Angelo Auricchio, chief medical officer for Rhythm Management at Boston Scientific in Europe, Middle East and Africa (EMEA). “Remotely monitoring worsening heart failure can also reduce inequities, particularly in underserved, lower socioeconomic and remote communities who may be more reluctant to travel to hospitals, helping to address a key priority of the NHS.”
The HeartLogic heart failure diagnostic, which has demonstrated accurate detection of patients at risk of heart failure events up to 34 days in advance, incorporates multiple sensors and combines trend data into one composite index, sending clinicians a single actionable alert and detailed report when it crosses a clinician-set threshold.
This allows early intervention and the potential to reduce patient hospitalisations. NICE found the HeartLogic diagnostic to be the most accurate and consistent of reviewed heart failure algorithms in the UK market.
